NCT05163106 - Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

July 30, 2024

Study Completion Date

July 30, 2024

Conditions

Breast CancerHER2-negative Breast CancerER-positive Breast CancerLocally Advanced Breast CancerLuminal A Breast CancerLuminal B Breast Cancer

Interventions

DRUG

Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet

Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.

DRUG

Goserelin

Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.

Trial Locations (1)

Akershus University Hospital, Lørenskog